Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

There is a dearth of studies on the efficacy and safety of the tyrosine kinase inhibitors osimertinib (OSI) and gefitinib (GEF) in treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), even in patients with poor performance status (PS). We retrospecti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory investigation 2024-11, Vol.62 (6), p.1137-1141
Hauptverfasser:	Nakashima, Kazuhisa, Kodama, Hiroaki, Murakami, Haruyasu, Takahashi, Toshiaki, Kawakado, Keita, Yanagawa, Takashi, Kitani, Kashu, Hottta, Takamasa, Abe, Masaaki, Hamai, Kosuke, Tanimoto, Takuya, Ishikawa, Nobuhisa, Tamura, Tomoki, Kuyama, Shoichi, Isobe, Takeshi, Tsubata, Yukari
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides - therapeutic use Aged Aged, 80 and over Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics EGFR mutation ErbB Receptors - genetics Female Gefitinib Gefitinib - administration & dosage Gefitinib - therapeutic use Humans Indoles Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Middle Aged Mutation Non-small-cell lung cancer Osimertinib Poor performance status Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Pyrimidines Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!